CLIMB BIO, INC. Net Income (Loss) Available to Common Stockholders, Basic
CLIMB BIO, INC. (CLYM) reported Net Income (Loss) Available to Common Stockholders, Basic of -$45.24 million for the 12-month period ending 2022-12-31, per its 10-K filed 2023-03-06.
Discontinued › Income Statement
us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic · last filed 2023-03-06
- CLIMB BIO, INC. net income (loss) available to common stockholders, basic for the quarter ending 2022-12-31 was -$7.76M.
- CLIMB BIO, INC. net income (loss) available to common stockholders, basic for the quarter ending 2022-09-30 was -$9.68M.
- CLIMB BIO, INC. net income (loss) available to common stockholders, basic for the quarter ending 2022-06-30 was -$14.60M.
- CLIMB BIO, INC. net income (loss) available to common stockholders, basic for the quarter ending 2022-03-31 was -$13.20M.
- CLIMB BIO, INC. net income (loss) available to common stockholders, basic for fiscal 2022 was -$45.24M.
- CLIMB BIO, INC. net income (loss) available to common stockholders, basic for fiscal 2021 was -$52.03M.
- CLIMB BIO, INC. net income (loss) available to common stockholders, basic for fiscal 2020 was -$22.95M.
| Period end | Net Income (Loss) Available to Common Stockholders, Basic 3 month | Net Income (Loss) Available to Common Stockholders, Basic 6 month | Net Income (Loss) Available to Common Stockholders, Basic 9 month | Net Income (Loss) Available to Common Stockholders, Basic 12 month |
|---|---|---|---|---|
| 2022-12-31 | -$7.76M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-06 | -$17.44M derived: sum of 2 quarters · filed 2023-03-06 | -$32.04M derived: sum of 3 quarters · filed 2023-03-06 | -$45.24M 10-K · filed 2023-03-06 |
| 2022-09-30 | -$9.68M 10-Q · filed 2022-11-14 | -$24.28M derived: sum of 2 quarters · filed 2022-11-14 | -$37.48M 10-Q · filed 2022-11-14 | -$48.03M derived: sum of 4 quarters · filed 2023-03-06 |
| 2022-06-30 | -$14.60M 10-Q · filed 2022-08-15 | -$27.80M 10-Q · filed 2022-08-15 | -$38.34M derived: sum of 3 quarters · filed 2023-03-06 | -$49.28M derived: sum of 4 quarters · filed 2023-03-06 |
| 2022-03-31 | -$13.20M 10-Q · filed 2022-05-16 | -$23.75M derived: sum of 2 quarters · filed 2023-03-06 | -$34.69M derived: sum of 3 quarters · filed 2023-03-06 | -$45.55M derived: sum of 4 quarters · filed 2023-03-06 |
| 2021-12-31 | -$10.54M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-06 | -$21.48M derived: sum of 2 quarters · filed 2023-03-06 | -$32.34M derived: sum of 3 quarters · filed 2023-03-06 | -$52.03M 10-K · filed 2023-03-06 |
| 2021-09-30 | -$10.94M 10-Q · filed 2022-11-14 | -$21.80M derived: sum of 2 quarters · filed 2022-11-14 | -$41.48M 10-Q · filed 2022-11-14 | -$57.28M derived: sum of 4 quarters · filed 2022-11-14 |
| 2021-06-30 | -$10.86M 10-Q · filed 2022-08-15 | -$30.55M 10-Q · filed 2022-08-15 | -$46.34M derived: sum of 3 quarters · filed 2022-08-15 | -$49.06M derived: sum of 4 quarters · filed 2022-08-15 |
| 2021-03-31 | -$19.69M 10-Q · filed 2022-05-16 | -$35.48M derived: sum of 2 quarters · filed 2022-05-16 | -$38.20M derived: sum of 3 quarters · filed 2022-05-16 | -$40.28M derived: sum of 4 quarters · filed 2022-05-16 |
| 2020-12-31 | -$15.80M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-07 | -$18.52M derived: sum of 2 quarters · filed 2022-03-07 | -$20.60M derived: sum of 3 quarters · filed 2022-03-07 | -$22.95M 10-K · filed 2022-03-07 |
| 2020-09-30 | -$2.72M 10-Q · filed 2021-11-08 | -$4.80M derived: sum of 2 quarters · filed 2021-11-08 | -$7.16M 10-Q · filed 2021-11-08 | |
| 2020-06-30 | -$2.08M 10-Q · filed 2021-09-13 | -$4.44M 10-Q · filed 2021-09-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |